WANG Zheng1, ZOU Jian-jun2, LI Zhe1, SHEN Su1, YU Jun-xian1*
1. Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China; 2. Department of New Drug Research and Development,Jiangsu Hengrui Medicine Co.,Ltd, Shanghai 200122, China
Abstract��Colorectal cancer is a common gastrointestinal cancer which always diagnosed too late. However, nowadays the median survival of patients has been effectively improved by chemotherapy plus targeted therapy. Targeted drugs on the market can be divided into two categories, monoclonal antibodies and small molecule kinase inhibitors(TKI). Bevacizumab, cetuximab, panitumumab, ramucirumab are monoclonal antibody. TKIs are as followed:regorafenib, ziv-aflibercept.According to the drug mechanism, bevacizumab and panitumumab target at epidermal growth factor receptor(EGFR)on tumor cells. While the remaining four drugs target at vascular endothelial growth factor(VEGF) and its receptor(VEGFR). Clinical trials of Chinese domestic drugs apatinib and famitinib are undergoing. Currently, the main issue of colorectal cancer targeted therapy is how to overcome drug resistance and reducetoxicity. The direction of future work is finding new targets, new drugs in colorectal cancer, such as PD-1 inhibitors which may bring new vitality to worldwide patients.
JEMAL A, BRAY F, CENTER M M, et al. Global cancer statistics [J]. CA Cancer J Clin, 2011, 61(2): 69-90.
[2]
SIEGEL R, MA J, ZOU Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1): 9-29.
[3]
CHEN W Q,ZHENG R S,ZHANG S W, et al. Report of cancer incidence and mortality in China, 2012 [J]. Chin Cancer(�����), 2016,25(1):1-8.
[4]
SIEGEL R, NAISHADHAM D, JEMAL A. Cancer statistics, 2012 [J].CA Cancer J Clin, 2012, 62(1):10-29.
[5]
ZHOU A P, WANG J W. Hot spots about target therapy of metastasis colorectal cancer on the 2013 ASCO conference[J]. Chin J New Drugs(�й���ҩ��־),2013, 22(17): 2033-2037.
[6]
ARNOLD D,RE T,BENNOUNA J, et al.Bevacizumab(BEV) plus chemotherapy(CT) continued beyond first progression in patients with metastatic colorectal cancer(mCRC) previously treated with BEV plus CT:results of a randomized phase III intergroup study(TML study) [J]. J Clin Oncol,2012,30(suppl):abstr CRA3503.
[7]
LEMMON M A,SCHLESSINGER J. Cell signaling by receptor tyrosine kinases [J]. Cell,2010,141(7): 1117-1134.
[8]
BROGNARD J,HUNTER T. Protein kinase signaling networks in cancer[J].Curr Opin Genet Dev, 2011, 21(1): 4-11.
[9]
ZAMECNIKOVA A. Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer [J]. Expert Opin Drug Discov,2014, 9(1): 77-92.
[10]
LEVITZKI A. Tyrosine kinase inhibitors: views of selectivity, sensitivity,and clinical performance [J]. Annu Rev Pharmacol Toxicol, 2013, 53: 161-185.
[11]
SAWYER T K, WU J C, SAWYER J R, et al. Protein kinase inhibitors: breakthrough medicines and the next generation[J]. M Expert Opin Invest Drugs, 2013, 22(6): 675-678.
[12]
HANG L, WANG J. The investigation of TKIs [J]. Chem Reagents(��ѧ�Լ�), 2014, 36(10): 901-906.
[13]
FOLKMAN J. Tumor angiogenesis: therapeutic implication [J]. N Engl J Med, 1971, 285(21): 1182-1186.
[14]
FRANCAVILLA C, MADDALUNO L, CAVALLARO U. The functional role of cell adhesion molecules in tumor angiogenesis [J]. Seminars Cancer Biol, 2009, 19(5): 298-309.
[15]
KISS I, BORTLICEK Z, MELICHAR B, et al. Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma [J]. Anticancer Res, 2014, 34(2):949-954.
[16]
AN X Y. The new strategies of targeted drugs[J]. Acta Biophys Sin(��������ѧ��), 2010, 26(3):180-193.
[17]
NAGY J A, DVORAK A M, DVORAK H F. VEGF-A and the induction of pathological angiogenesis [J]. Annu Rev Pathol Mech Dis, 2007, 2: 251-275.
[18]
JIN C H, WANG A H, CHEN J M, et al. Observation of curative efficacy and prognosis following combination chemotherapy with celecoxib in the treatment of advanced colorectal cancer[J]. J Int Med Res, 2011, 39(6):2129-2140.
[19]
HURWITZ H, FEHRENBACHER L, NOVOTNY W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J]. N Engl J Med, 2004, 350(23): 2335-2342.
[20]
EI B X, ZHANG Z Y, XU Y P. Clinical research of bevacizumab plus different kinds of chemotherapieutics for metastatic colorectalcancer[J]. Chin Pharm J(�й�ҩѧ��־), 2014,49(22):2039-2042.
[21]
IAN W L, HAN W,TANG S Z. Progress in research of multi-target drugs and their development strategy [J]. Guangdong Chem Ind(�㶫����), 2014,8(41):69-72.
[22]
SARTORE A, ZEEPELLINI A, AMATU A, et al. Regorafenib in metastatic colorectal cancer [J]. Expert Rev Anticancer Ther, 2014, 14(3): 255-265.
[23]
QI Y. The approval of ziv-aflibercept by FDA [J]. J Int Pharm Res(����ҩѧ�о���־), 2012, 39(5): 390.
[24]
SONG M. Progression of ziv-aflibercept on metastatic colorectal cancer [J]. Chin J New Drugs Clin Rem(�й���ҩ���ٴ���־), 2015,9(34):692-696.
[25]
LI J, QIN S, XU J, et al. Randomized, double-blind, placebo-controlled phase iii trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J]. Clin Oncol,2016, 34(13):1448-1454.
[26]
LANKHORST S,KAPPERS M H, VAN ESCH J H,et al. Hypertension during vascular endothelial growth factor inhibition: focus on nitricoxide,endothelin-1,and oxidative stress[J]. Antioxid Redox Signal,2014,20(1): 135-145.
[27]
ZHOU A, ZHANG W, CHANG C, et al. Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib[J].Cancer Chemother Pharmacol, 2013, 72(5):1043-1053.
[28]
LI H M, YU Y H. Key molecules in targeted therapies for metastatic colorectal cancer [J]. World Chin J Digestol(���绪��������־), 2014, 22(3): 350-358.
[29]
SHEEMA S, ROBERTO B, PAOLO M, et al. Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer[J]. J Theor Biol,2016,389:263-273.
[30]
HU J X, FAN X M. Research progress of targeted therapy in colorectal cancer [J]. World Clin Drugs(�����ٴ�ҩ��), 2015, 36(6):366-369.
[31]
MCLELLAN B, CIARDIELLO F, LACOUTURE E, et al.Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management [J]. Annals Oncol, 2015,10(26): 2017-2026.
[32]
LU Y Y, GUO X L. Advance development of immunotherapy on malignant melanoma with targeting inhibition of PD-L1/PD-1[J]. Chin Pharm J(�й�ҩѧ��־),2015, 50(22):1931-1935.
[33]
ZHANG X W, REN X B. The clinical research of PD-1inhibitors [J]. Med Philosophy(ҽѧ����ѧ),2015,36(2):22-28.
2016, Vol. 51 
